Fifty percent recruitment milestone for PROPELLER prostate cancer trial

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...

Related Keywords

United States ,Australia ,American ,Alan Taylor ,Simon Hinsley ,National Cancer Institute ,Clarity Pharmaceuticals ,Technology Platform ,Cancer Statistics Center ,American Cancer Society ,Executive Chairman ,Phasei Positron Emission Tomography ,Louise Emmett ,Hospital Sydney ,Principal Investigator ,Targeted Copper Theranostics ,Cancer Statistics ,Mortality Worldwide ,Cancer Society ,